Protein-Protein Interaction Activates and Fuels Leukemia Cell Growth

Findings also show how an experimental monoclonal antibody treatment inhibits growth and spread of cancer

Stained chronic lymphocytic leukemia cells.

Stained chronic lymphocytic leukemia cells.

Building upon previous research, scientists at University of California, San Diego School of Medicine and UC San Diego Moores Cancer report that a protein called Wnt5a acts on a pair of tumor-surface proteins, called ROR1 and ROR2, to accelerate the proliferation and spread of chronic lymphocytic leukemia (CLL) cells, the most common form of blood cancer in adults.

They note, however, that these effects of Wnt5a were blocked by a humanized monoclonal antibody specific for ROR1, called cirmtuzumab (or UC-961), which inhibited the growth and spread of CLL cells in both cell lines and mouse models of leukemia. The findings are published in the December 21, 2015 issue of The Journal of Clinical Investigation.

Continue reading about Blood Cancer Research Funded research